Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.42 |
| ▸ | SCN8A | Q9UQD0 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MAPT | P10636 | 3/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1576449 | 0.94 | SCN8A (0.44) | SCN9ASCN8ACYP3A4ALDH1A1MAPT | |
| SCHEMBL2625934 | 0.90 | SMN1; SMN2 (0.49) | SCN9ASCN8ACYP3A4ALDH1A1MAPT | |
| SCHEMBL2626329 | 0.85 | SMN1; SMN2 (0.47) | SCN9ASCN8ACYP3A4ALDH1A1MAPT | |
| SCHEMBL2626085 | 0.85 | ALDH1A1 (0.51) | SCN9ASCN8AALDH1A1MAPTMAPK1 | |
| SCHEMBL2626059 | 0.85 | SCN9A (0.46) | SCN9ASCN8ACYP3A4ALDH1A1MAPT | |
| SCHEMBL2626058 | 0.84 | ALDH1A1 (0.48) | SCN9ASCN8AALDH1A1MAPTMAPK1 | |
| SCHEMBL2626025 | 0.84 | MAPT (0.53) | SCN9ASCN8AALDH1A1MAPTHTT | |
| SCHEMBL2626137 | 0.83 | SCN9A (0.48) | SCN9ASCN8AALDH1A1MAPTMAPK1 | |
| SCHEMBL14683825 | 0.83 | SCN9A (0.44) | SCN9ASCN8AALDH1A1MAPTMAPK1 | |
| SCHEMBL2626207 | 0.82 | SCN8A (0.42) | SCN9ASCN8AALDH1A1HTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309587-B2 | Piperidine and piperazine phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-11-13 | — | — | US | disclosed |
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-07-12 | — | — | US | disclosed |
| US-8163720-B2 | Pyrrolidinyl phenyl sulphonamides as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-04-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178713-A1 | PHENYL SULPHONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, TRPA1, TRPV5 | SCN9A 81/4885SCN8A 62/4885CYP3A4 2767/4885 |
| US-20110082117-A1 | PHENYL SULFONAMIDES AS MODULATORS OF ION CHANNELS | TRPV1, KCNJ2, TRPA1 | SCN9A 104/4885SCN8A 78/4885CYP3A4 2502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.